Abstract
A series of new phthalazine derivatives 3a–i and 4a–c were synthesized via the reaction of 1-chlorophthalazine derivative 2 with either N-substituted-piperazines, primary or their secondary amines. The structure of the synthesized, new compounds were characterized by spectral data. The anti-proliferative activity on human breast cancer cell line MCF-7 of the synthesized compounds was determined. The results showed that six of the test compounds (3a, 3g, 3i, and 4a–c) displayed potent cytotoxic activity ranging from 1.4 to 2.3 μmol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albrand G, Terret C (2008) Early breast cancer in the elderly: assessment and management considerations. Drugs Aging 25:35–45
Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107
Colotta V, Cecchi L, Catarzi D, Filacchioni G, Galli A, Mori F (1994) Synthesis and structure-activity relationships of 1-aminophthalazinium salts as GABAA receptor antagonists. Eur J Med Chem 29:95–105
Hennequin LF, Allen J, Breed J et al (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49:6465–6488
Menear KA, Adcock C, Alonso FC et al (2008a) Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Bioorg Med Chem Lett 18:3942–3945
Menear KA, Adcock C, Boulter R et al (2008b) 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51:6581–6591
Miller-Moslin K, Peukert S, Jain RK et al (2009) 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 52:3954–3968
Pollard JR, Mortimore M (2009) Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 52:2629–2651
Scott EN, Meinhardt G, Jacques C et al (2007) Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 16:367–379
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
Vasiliou S, Castaner R, Bolos J et al (2009) SNS-032-cyclin-dependent kinase inhibitor oncolytic. Drugs of the Future 34:101–105
Wang X, Bastow KF, Sun CM, Lin YL, Yu HJ, Don MJ, Wu TS, Nakamura S, Lee KH (2004) Antitumor agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J Med Chem 47:5816–5819
Xin Z, Juan L, Lei H, Su Z, Yao Bin Z, Ping G (2008) Synthesis and in vitro cytotoxicity of novel 1,4-disubstituted phthalazines. Chinese Chem Lett 19(1):29–32
Yamaguchi M, Kamei K, Koga T, Akima M, Kuroki T, Ohi N (1993) Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1,2-[2-(1-imidazolyl)alkyl]-1(2H)-phthalazinones. J Med Chem 36:4052–4060
Zhang S, Zhao Y, Liu Y, Chen D, Lan W, Zhao Q, Dong C, Xia L, Gong P (2010) Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur J Med Chem 45:3504–3510
Acknowledgment
The authors are grateful to Dr. Ashraf Bahi Abd El-Naim, Professor of Pharmacology, Faculty of Pharmacy, Ain Shams University, for carrying out anti-proliferative activity.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abouzid, K.A.M., Khalil, N.A. & Ahmed, E.M. Synthesis and evaluation of anti-proliferative activity of 1,4-disubstituted phthalazines. Med Chem Res 21, 3288–3293 (2012). https://doi.org/10.1007/s00044-011-9874-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-011-9874-z